Integrated Multi-Omics Profiling Yields a Clinically Relevant Molecular Classification for Esophageal Squamous Cell Carcinoma.
Zhihuai Liu,Yahui Zhao,Pengzhou Kong,Yuhao Liu,Jing Huang,Enwei Xu,Wenqing Wei,Guangyu Li,Xiaolong Cheng,Liyan Xue,Yi Li,Hongyan Chen,Shuqing Wei,Ruifang Sun,Heyang Cui,Yongsheng Meng,Meilin Liu,Yang Li,Riyue Feng,Xiao Yu,Rui Zhu,Yenan Wu,Lei Li,Bin Yang,Yanchun Ma,Jiawei Wang,Wenjie Zhu,Dongjie Deng,Yanfeng Xi,Fang Wang,Hongyi Li,Shiping Guo,Xiaofei Zhuang,Xiaoyue Wang,Yuchen Jiao,Yongping Cui,Qimin Zhan
DOI: https://doi.org/10.1016/j.ccell.2022.12.004
IF: 50.3
2023-01-01
Cancer Cell
Abstract:Integrated molecular analysis of human cancer has yielded molecular classification for precise management of cancer patients. Here, we analyzed the whole genomic, epigenomic, transcriptomic, and proteomic data of 155 esophageal squamous cell carcinomas (ESCCs). Multi-omics analysis led to the classification of ESCCs into four subtypes: cell cycle pathway activation, NRF2 oncogenic activation, immune suppression (IS), and immune modulation (IM). IS and IM cases were highly immune infiltrated but differed in the type and distribution of immune cells. IM cases showed better response to immune checkpoint blockade therapy than other subtypes in a clinical trial. We further developed a classifier with 28 features to identify the IM subtype, which predicted anti-PD-1 therapy response with 85.7% sensitivity and 90% specificity. These results emphasize the clinical value of unbiased molecular classification based on multi-omics data and have the potential to further improve the understanding and treatment of ESCC.